Empros and Megapharm announce letter of intent

Press release

Empros Pharma AB (“Empros Pharma” or “Empros”) and Megapharm Ltd. (“Megapharm”) announce
today that they have entered into a Letter of Intent (“LOI”) for EMP16, Empros’s product for the
treatment of overweight and obesity which is currently under development.
Both parties have declared their mutual intent to enter into a license agreement concerning the
commercialization of EMP16 through the signing of a Letter of Intent. Megapharm has both the
capacity and expertise to in-license, register, market and distribute EMP16 in Israel. Under the LOI,
Empros is willing to assign to Megapharm exclusive distribution rights for EMP16 in the territory.
Arvid Söderhäll, CEO of Empros commented “We are excited to have signed this Letter of Intent with
Megapharm and this represents the first publicly announced interest in the commercial potential of
EMP16. This is of major importance to Empros and gives us the confidence to continue to expand and
accelerate our market development activities towards a future launch”.
Miron Drucker, CEO of Megapharm added “There is a clear need for a first line obesity treatment in
Israel and we believe that EMP16 has the potential to fulfil this. We are excited by the prospect of
the collaboration and look forward to working with Empros to bring the product to market”.
Canaccord Genuity is acting as exclusive business development advisor for EMP16 and organizations
with an interest to commercialize EMP16 are encouraged to contact Issac Jacob at Canaccord.


Empros Pharma develops EMP16, a pharmaceutical treatment against overweight and obesity.
Empros Pharma AB was founded in late 2013 by senior researchers and entrepreneurs at Uppsala
University together with the external investor Flerie Invest. The EMP16 product has demonstrated its
efficacy in a proof-of-concept clinical trial, as recently published in Obesity: Effects of a novel weight‐
loss combination product containing orlistat and acarbose on obesity: A randomized, placebo‐
controlled trial – Holmbäck – 2022 – Obesity – Wiley Online Library.
Empros continues to progress the clinical development of EMP16 in two more clinical trials that will
run during 2023. The early phase safety and tolerability trial finalized in 2017 demonstrated a bestin-class safety profile and improved blood glucose control.


Megapharm Ltd. is one of the leading privately held pharmaceutical companies in Israel, expert in
marketing and distribution in the pharmaceutical and healthcare industry. Founded in 1989,
Megapharm has more than 33 years successful track record for introducing and commercializing
innovative treatments in Israel. Megapharm has established partnerships with numerous
international companies, leading to a dynamic growth in sales. Megapharm’s core expertise are
within: Oncology and Hematology-Oncology, CNS, Orphan and Metabolic drugs. Maintaining longstanding relations with Ministry of Health, Health Funds, hospitals, local medical centers, physicians
and KOLs. Operating under strict GMP and ISO standards – ensuring that all procedures and business
conducts are of the highest market standards.

Read the press release

Share the Post: